Indicated in adults for:1

  • Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures, but not hip fractures, has been demonstrated.
  • Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Reference: 1. SONDELBAY® Summary of Product Characteristics.

SONDELBAY® (teriparatide) Summary of Product Characteristics (SmPC), legal category, cost and adverse event reporting:
Legal Category POM: Prescription only medicine
NHS list prices:
1 Pen: £271.87
3 Pens: £815.61
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk
Adverse events should also be reported to Accord-UK LTD on 01271 385257 or email medinfo@accord-healthcare.com
  • © Copyright Accord-UK 2025
  • UK-04004
  • Date of preparation: April 2025